Other languages Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
9.78 ^USD	+1.56%		+15.06%	+139.71%

18/04	Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development	CI
09/04	Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development	19/04
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	01/03
Sector Update: Health Care Stocks Edge Higher Premarket Friday	01/03
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline	01/03
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/03
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	17/02
Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP	14/02
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	13/02
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing	13/02
Sana Biotechnology Says US FDA Approved Investigational New Drug Application to Launch Clinical Trial for SC262	05/01
Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262	05/01
Sana Biotechnology Insider Sold Shares Worth $300,098, According to a Recent SEC Filing	19/12
Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting	11/12
Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System	02/12
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis	10/11
Sana Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Sana Biotechnology to Cut Spending on Fusogen Platform, Delaying SG299 IND; Workforce Slashed by 29%; Shares Rise	11/23/11
Sana Biotechnology, Inc. Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with A 2024 Operating Burn Under $200M	11/23/11
Sana Biotechnology Shares Rise After Citigroup Starts Coverage at Buy	05/23/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Other languages

Filters